Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Gemini 2.5 Pro in Google AI Studio is priced at $1.25 per million input tokens and $10 per million output tokens.

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

The Centers for Medicare and Medicaid Services estimates U.S. health care spending will grow 5.6% annually through 2032, ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Health tech companies made several major funding announcements in March. Here is a list of some of the biggest funding rounds.

If you’re looking for trail shoes that are lightweight, flashy, and fun, look no more because the Arc’teryx Vertex Speed ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...